170 related articles for article (PubMed ID: 37945162)
1. Treatment of Autoimmune Hepatitis.
Goel A; Kwo P
Clin Liver Dis; 2024 Feb; 28(1):51-61. PubMed ID: 37945162
[TBL] [Abstract][Full Text] [Related]
2. Current and prospective pharmacotherapy for autoimmune hepatitis.
Czaja AJ
Expert Opin Pharmacother; 2014 Aug; 15(12):1715-36. PubMed ID: 24961409
[TBL] [Abstract][Full Text] [Related]
3. Everolimus treatment for patients with autoimmune hepatitis and poor response to standard therapy and drug alternatives in use.
Ytting H; Larsen FS
Scand J Gastroenterol; 2015 Aug; 50(8):1025-31. PubMed ID: 25862144
[TBL] [Abstract][Full Text] [Related]
4. Histological changes after the use of mycophenolate mofetil in autoimmune hepatitis.
Brunt EM; Di Bisceglie AM
Hum Pathol; 2004 Apr; 35(4):509-12. PubMed ID: 15116334
[TBL] [Abstract][Full Text] [Related]
5. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes.
Baven-Pronk AM; Coenraad MJ; van Buuren HR; de Man RA; van Erpecum KJ; Lamers MM; Drenth JP; van den Berg AP; Beuers UH; den Ouden J; Koek GH; van Nieuwkerk CM; Bouma G; Brouwer JT; van Hoek B
Aliment Pharmacol Ther; 2011 Aug; 34(3):335-43. PubMed ID: 21668459
[TBL] [Abstract][Full Text] [Related]
6. Current and novel immunosuppressive therapy for autoimmune hepatitis.
Heneghan MA; McFarlane IG
Hepatology; 2002 Jan; 35(1):7-13. PubMed ID: 11786954
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy.
Roberts SK; Lim R; Strasser S; Nicoll A; Gazzola A; Mitchell J; Siow W; Khoo T; Hamarneh Z; Weltman M; Gow P; Janko N; Tse E; Mishra G; Cheng EH; Levy M; Cheng W; Sood S; Skoien R; Mitchell J; Zekry A; George J; MacQuillan G; Wigg A; Stuart K; Sievert W; McCaughan G;
Clin Gastroenterol Hepatol; 2018 Feb; 16(2):268-277. PubMed ID: 29050991
[TBL] [Abstract][Full Text] [Related]
8. Autoimmune hepatitis: Azathioprine or mycophenolate mofetil for inducing remission?
Tiwari A; Khanikar D; Rathod SG
J Hepatol; 2024 Jul; 81(1):e38-e39. PubMed ID: 38403031
[No Abstract] [Full Text] [Related]
9. An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis.
Snijders RJALM; Stoelinga AEC; Gevers TJG; Pape S; Biewenga M; Tushuizen ME; Verdonk RC; de Jonge HJM; Vrolijk JM; Bakker SF; Vanwolleghem T; de Boer YS; Baven Pronk MAMC; Beuers U; van der Meer AJ; Gerven NMFV; Sijtsma MGM; van Eijck BC; van IJzendoorn MC; van Herwaarden M; van den Brand FF; Korkmaz KS; van den Berg AP; Guichelaar MMJ; Levens AD; van Hoek B; Drenth JPH;
J Hepatol; 2024 Apr; 80(4):576-585. PubMed ID: 38101756
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine.
Richardson PD; James PD; Ryder SD
J Hepatol; 2000 Sep; 33(3):371-5. PubMed ID: 11019991
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate mofetil as an alternative treatment for autoimmune hepatitis.
Park SW; Um SH; Lee HA; Kim SH; Sim Y; Yim SY; Seo YS; Ryu HS
Clin Mol Hepatol; 2016 Jun; 22(2):281-5. PubMed ID: 27246353
[TBL] [Abstract][Full Text] [Related]
12. The use of immunosuppression in autoimmune hepatitis: A current literature review.
Cropley A; Weltman M
Clin Mol Hepatol; 2017 Mar; 23(1):22-26. PubMed ID: 28288505
[TBL] [Abstract][Full Text] [Related]
13. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease.
Czaja AJ; Carpenter HA
J Clin Gastroenterol; 2005 Oct; 39(9):819-25. PubMed ID: 16145346
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of children and young adults with autoimmune hepatitis treated with cyclosporine.
Nastasio S; Sciveres M; Matarazzo L; Malaventura C; Cirillo F; Riva S; Maggiore G
Dig Liver Dis; 2019 May; 51(5):712-718. PubMed ID: 30502231
[TBL] [Abstract][Full Text] [Related]
15. Drug choices in autoimmune hepatitis: part B--Nonsteroids.
Czaja AJ
Expert Rev Gastroenterol Hepatol; 2012 Sep; 6(5):617-35. PubMed ID: 23061712
[TBL] [Abstract][Full Text] [Related]
16. Mycophenolate mofetil as a rescue therapy for autoimmune hepatitis patients who are not responsive to standard therapy.
Fallatah HI; Akbar HO
Expert Rev Gastroenterol Hepatol; 2011 Aug; 5(4):517-22. PubMed ID: 21780898
[TBL] [Abstract][Full Text] [Related]
17. Autoimmune hepatitis: Mycophenolate mofetil vs. azathioprine as first-line therapy.
Şimşek C; Wahlin S; Efe C
J Hepatol; 2024 Jul; 81(1):e41-e42. PubMed ID: 38458322
[No Abstract] [Full Text] [Related]
18. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients.
Zachou K; Gatselis N; Papadamou G; Rigopoulou EI; Dalekos GN
J Hepatol; 2011 Sep; 55(3):636-646. PubMed ID: 21238519
[TBL] [Abstract][Full Text] [Related]
19. Survival Associated With Sirolimus Plus Tacrolimus Maintenance Without Induction Therapy Compared With Standard Immunosuppression After Lung Transplant.
Wijesinha M; Hirshon JM; Terrin M; Magder L; Brown C; Stafford K; Iacono A
JAMA Netw Open; 2019 Aug; 2(8):e1910297. PubMed ID: 31461151
[TBL] [Abstract][Full Text] [Related]
20. Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis.
Efe C; Taii HA; Ytting H; Aehling N; Bhanji RA; Hagström H; Purnak T; Muratori L; Werner M; Muratori P; Klintman D; Schiano TD; Montano-Loza AJ; Berg T; Larsen FS; Alkhouri N; Ozaslan E; Heneghan MA; Yoshida EM; Wahlin S
Dig Dis Sci; 2018 May; 63(5):1348-1354. PubMed ID: 29569003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
